Literature DB >> 1906888

Binding of tissue-type plasminogen activator by the mannose receptor.

M Otter1, M M Barrett-Bergshoeff, D C Rijken.   

Abstract

Previous studies have shown that tissue-type plasminogen activator (t-PA) in blood is cleared by the liver partially through a mannose-specific uptake system. The present study was undertaken to investigate, in a purified system, whether t-PA is recognized by the mannose receptor which is expressed on macrophages and liver sinusoidal cells. The mannose receptor was isolated and purified from bovine alveolar macrophages and migrated as a single protein band at Mr 175,000 on polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate. Ligand blotting revealed that this protein specifically bound t-PA. The t-PA-receptor interaction was further characterized in a binding assay, which showed saturable binding with an apparent dissociation constant of 1 nM. t-PA binding required calcium ions and was negligible in the presence of EDTA or at acid pH. Mannose-albumin was an effective inhibitor, whereas galactose-albumin did not have a significant effect. From a series of monosaccharides tested, D-mannose and L-fucose were the most potent inhibitors, N-acetyl-D-glucosamine was a moderate inhibitor, whereas D-galactose and N-acetyl-D-galactosamine were ineffective. t-PA, deglycosylated by endoglycosidase H, did not interact with the receptor. It is concluded that the mannose receptor specifically binds t-PA, probably through its high mannose-type oligosaccharide.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1906888

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

1.  Role of tissue plasminogen activator receptor LRP in hippocampal long-term potentiation.

Authors:  M Zhuo; D M Holtzman; Y Li; H Osaka; J DeMaro; M Jacquin; G Bu
Journal:  J Neurosci       Date:  2000-01-15       Impact factor: 6.167

2.  Collagen binding by the mannose receptor mediated through the fibronectin type II domain.

Authors:  Catherine E Napper; Kurt Drickamer; Maureen E Taylor
Journal:  Biochem J       Date:  2006-05-01       Impact factor: 3.857

3.  A single-species approach considering additional physiological information for prediction of hepatic clearance of glycoprotein derivate therapeutics.

Authors:  Patrick Poulin
Journal:  Clin Pharmacokinet       Date:  2011-10       Impact factor: 6.447

Review 4.  Design and creativity in synthesis of multivalent neoglycoconjugates.

Authors:  Yoann M Chabre; René Roy
Journal:  Adv Carbohydr Chem Biochem       Date:  2010       Impact factor: 12.200

5.  Tissue-type plasminogen activator: a role for O-linked fucose.

Authors:  J U Baenziger
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

6.  Involvement of the mannose receptor in infection of macrophages by influenza virus.

Authors:  P C Reading; J L Miller; E M Anders
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

7.  Enhancement of macrophage candidacidal activity by interferon-gamma. Increased phagocytosis, killing, and calcium signal mediated by a decreased number of mannose receptors.

Authors:  L Maródi; S Schreiber; D C Anderson; R P MacDermott; H M Korchak; R B Johnston
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

8.  Interleukin-4-induced macrophage fusion is prevented by inhibitors of mannose receptor activity.

Authors:  A K McNally; K M DeFife; J M Anderson
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

9.  Characterization of the interaction both in vitro and in vivo of tissue-type plasminogen activator (t-PA) with rat liver cells. Effects of monoclonal antibodies to t-PA.

Authors:  M Otter; J Kuiper; R Bos; D C Rijken; T J van Berkel
Journal:  Biochem J       Date:  1992-06-01       Impact factor: 3.857

10.  Characterization of the binding of plasminogen activators to plasma membranes from human liver.

Authors:  G Nguyen; S J Self; C Camani; E K Kruithof
Journal:  Biochem J       Date:  1992-11-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.